Pembrolizumab with stereotactic body radiotherapy for unresected stage I or II non-small cell lung cancer

Pembrolizumab with stereotactic body radiotherapy (SBRT) is currently in development for patients with
unresected stage I or II (stage IIB N0, M0) non-small cell lung cancer (NSCLC). NSCLC is the most common
type of lung cancer. Stage I NSCLC is small; contained inside the lung and has not spread to lymph nodes;
and stage IIB is up to 5cm in size and has spread into nearby lymph nodes, or between 5cm and 7cm but
has not spread into any lymph nodes. Unresected cancer is that which has not been either partly or
completely removed by surgery. Some symptoms of lung cancer include persistent or chronic cough;
coughing up blood; persistent breathlessness; loss of appetite or unexplained weight loss. Treatment
options for unresected stage I or II NSCLC are however very limited.